PDGFRB and cholangiocarcinoma: PDGFR inhibitors have demonstrated effective antitumor activity in several solid tumors, including gastrointestinal stromal tumors, prostate cancer, non-small cell lung cancer (NSCLC), and CCA [11,12,13,14].